TAK-659

DRUG12 trials

Sponsors

Calithera Biosciences, Inc, Millennium Pharmaceuticals, Inc., H Scott Boswell

Conditions

AMLAML, AdultAcute Myelogenous LeukemiaAdvanced Solid NeoplasmsAdvanced Solid Tumor and Lymphoma MalignanciesAdvanced Solid TumorsAdvanced and Metastatic Gastric or Gastroesophageal AdenocarcinomaCarcinoma, Non-Small-Cell Lung

Phase 1

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

CompletedNCT02000934

Calithera Biosciences, IncAdvanced Solid Tumor and Lymphoma Malignancies

Start: 2013-12-31End: 2021-06-29Updated: 2023-02-08

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

TerminatedNCT02323113

Calithera Biosciences, IncAcute Myelogenous Leukemia

Start: 2015-03-09End: 2018-08-15Updated: 2023-02-08

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

TerminatedNCT02551055

Millennium Pharmaceuticals, Inc.Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

Start: 2015-10-15End: 2017-02-17Updated: 2019-09-20

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

TerminatedNCT02834247

Calithera Biosciences, IncAdvanced Solid Tumors, Carcinoma, Non-Small-Cell Lung, Head and Neck Carcinoma, Squamous Cell +1

Start: 2016-08-12End: 2018-11-30Updated: 2023-02-08

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

TerminatedNCT02954406

Millennium Pharmaceuticals, Inc.Lymphoma, Non-Hodgkin

Start: 2017-03-05End: 2020-07-27Updated: 2022-02-18

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

TerminatedNCT03238651

Calithera Biosciences, IncLymphoma, Follicular, Marginal Zone, Lymphoma, Non-Hodgkin

Start: 2017-08-01End: 2020-08-17Updated: 2023-02-08

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

WithdrawnNCT03338881

Calithera Biosciences, IncAdvanced Solid Neoplasms, Lymphoma Neoplasms

Start: 2018-05-10End: 2019-05-01Updated: 2023-02-08

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

CompletedNCT03357627

Calithera Biosciences, IncLymphoma, Follicular, Lymphoma, Large B-cell, Diffuse, Lymphoma, Non-Hodgkin

Start: 2018-02-16End: 2021-08-03Updated: 2023-02-08

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

WithdrawnNCT03359733

Calithera Biosciences, IncAdvanced Solid Neoplasms, Lymphoma, Malignant

Start: 2018-02-28End: 2019-08-20Updated: 2023-02-08

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

WithdrawnNCT03772288

Calithera Biosciences, IncLymphoma, Non-Hodgkin

Start: 2019-04-03End: 2021-11-17Updated: 2023-02-08

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

TerminatedNCT04079738

H Scott BoswellAML, AML, Adult

Start: 2019-09-20End: 2022-02-23Updated: 2023-09-13

Phase 2

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

TerminatedNCT03123393

Calithera Biosciences, IncDiffuse Large B-cell Lymphoma

Start: 2017-10-10End: 2019-12-17Updated: 2023-02-08

Related Papers

FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML

npj Precision Oncology2026-02-26

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

Cancer Medicine2024-03-016 citations

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)

Oncotarget2023-01-265 citations

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

Haematologica2022-10-1313 citations

Abstract 5516: Immunological effects of SYK inhibition using TAK659 in patients diagnosed with diffuse large B cell lymphoma

Cancer Research2020-08-151 citations

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood2019-11-133 citations

Phase 1b study of TAK-659 + nivolumab (nivo) in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2018-05-203 citations

TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.

Journal of Clinical Oncology2018-05-20

A phase 1b study to evaluate TAK-659 in combination with nivolumab in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2017-05-202 citations

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Blood2016-12-0211 citations

Anti-tumor activity of TAK-659, a dual inhibitor of SYK and FLT-3 kinases, in AML models.

Journal of Clinical Oncology2016-05-208 citations

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Blood2015-12-0310 citations

Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models.

Journal of Clinical Oncology2014-05-206 citations